|
|
Vaccine Detail
|
Oncolytic Adenovirus Encoding GM-CSF Vaccine |
| Vaccine Information |
- Vaccine Name: Oncolytic Adenovirus Encoding GM-CSF Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007000
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- GM-CSF (human)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: CRC cells were infected with rAd.DCN.GM, an oncolytic adenovirus, expressed decorin and GM-CSF, and produced cytotoxicity (Liu et al., 2017).
- Description: This is for Bladder Cancer(NCT00109655). A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death (Liu et al., 2017; NCIT_C48412).
|
| Host Response |
|
|
| References |
Liu et al., 2017: Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, Xiao F, Bai Z, Yao H, Ma X, Jin L, Wu C, Seth P, Zhang Z, Wang L. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation. Human gene therapy. 2017; 28(8); 667-680. [PubMed: 28530155].
NCIT_C48412: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48412]
NCT00109655: [https://clinicaltrials.gov/ct2/show/NCT00109655?term=CG0070&rank=1]
|
|
